Pressmeddelande

BioStock: Curasight CEO comments on capital raise and milestone

Cision Publicerad: 25 Jun 09:15

Curasight has enrolled the first patient in its phase II trial with uTRACE in prostate cancer, activating a second USD 500,000 payment from partner Curium. Curasight also announced a capital raise aimed at further strengthening the company’s finances. The fund raise, which includes a directed share issue, a loan facility, and warrants will initially provide DKK 27.8 million, and the package could eventually provide up to DKK 120 million.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/curasight-ceo-comments-on-capital-raise-and-milestone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Curasight

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!